Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 8/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | F13A1 | P00488 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL420407 | 1.00 | TBXAS1 (0.50) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL20659611 | 1.00 | TBXAS1 (0.50) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL1892347 | 1.00 | TBXAS1 (0.50) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL1898999 | 1.00 | TBXAS1 (0.50) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL1650867 | 0.93 | TBXAS1 (0.41) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL29267785 | 0.86 | TBXAS1 (0.43) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL6532553 | 0.86 | TBXAS1 (0.36) | TBXAS1CYP1A2CYP2C19 | |
| SCHEMBL2704416 | 0.85 | CHRM1 (0.39) | TBXAS1LMNAFFAR1ALDH1A1 | |
| SCHEMBL12287350 | 0.84 | PAOX (0.38) | TBXAS1MAPTALDH1A1 | |
| SCHEMBL12287701 | 0.84 | PAOX (0.38) | TBXAS1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190112348-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2019-04-18 | — | — | US | disclosed |
| US-10259856-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2019-04-16 | — | — | US | disclosed |
| US-9688737-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2017-06-27 | — | — | US | disclosed |
| EP-2910570-B1 | Protease stabilized, acylated insulin analogues | NOVO NORDISK AS (DK) | 2016-10-12 | — | — | EP | disclosed |
| EP-2910571-B1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2016-10-05 | — | — | EP | disclosed |
| EP-2254906-B1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2016-10-05 | — | — | EP | disclosed |
| EP-2910569-B1 | Protease stabilized, acylated insulin analogues | NOVO NORDISK AS (DK) | 2016-10-05 | — | — | EP | disclosed |
| EP-2910569-A1 | Protease stabilized, acylated insulin analogues | Novo Nordisk A/S (DK) | 2015-08-26 | — | — | EP | disclosed |
| EP-2910571-A1 | Protease stabilized, acylated insulin analogues | Novo Nordisk A/S (DK) | 2015-08-26 | — | — | EP | disclosed |
| EP-2910570-A1 | Protease stabilized, acylated insulin analogues | Novo Nordisk A/S (DK) | 2015-08-26 | — | — | EP | disclosed |
| US-20150210748-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | disclosed |
| US-20150210747-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | disclosed |
| US-9045560-B2 | Protease stabilized, acylated insulin analogues | NOVO NORDISK A/S (DK) | 2015-06-02 | — | — | US | disclosed |
| US-20140073564-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2014-03-13 | — | — | US | disclosed |
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2011-05-05 | — | — | US | disclosed |
| CN-102037008-A | Protease stabilized, acylated insulin analogues | NOVO NORDISK AS | 2011-04-27 | — | — | CN | disclosed |
| EP-2254906-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | Novo Nordisk A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009115469-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210747-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | TBXAS1 2326/4885LMNA 1825/4885TSHR 807/4885 |
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | TBXAS1 2248/4885LMNA 1619/4885TSHR 819/4885 |
| US-20140073564-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | TBXAS1 2248/4885LMNA 1619/4885TSHR 819/4885 |
| US-20150210748-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | TBXAS1 2326/4885LMNA 1825/4885TSHR 807/4885 |
| US-20190112348-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | TBXAS1 2248/4885LMNA 1619/4885TSHR 819/4885 |
| US-10259856-B2 | Protease stabilized acylated insulin analogues | IAPP, IDE, LIPE | TBXAS1 2326/4885LMNA 1825/4885TSHR 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.